Analysis for Vertex Pharmaceuticals
Analysis summary
Vertex Pharmaceuticals (VRTX) currently has a total score of 65 points, placing it in the strong range. The score is made up of Performance (75), Stability (54) and Trend (57).
Performance scores 75 points (strong). Key strength: 10Y return at 480.3 %. Main drag: 1Y return at 2.9 %. This suggests stronger long-term than short-term performance.
Stability scores 54 points (neutral). Key strength: CAGR/drawdown ratio at 0.39. Weaker metric: volatility (365d, annualized) at 34.1 %. That implies elevated swings. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 57 points (neutral). Key strength: trend strength at 0.91. Weaker metric: 12M momentum at -5.1 %.
Overall, the score is shaped most by Performance; Stability trails and dampens the total. On a metric level, trend strength stands out, while 12M momentum is the main weak spot.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Vertex Pharmaceuticals fit best in FoxScore?
- Vertex Pharmaceuticals fits a more opportunity-seeking investor type in FoxScore: performance is the strongest sub-score. That suggests above-average historical returns — but check stability to ensure the performance wasn’t “paid for” with high volatility or deep drawdowns.
- How meaningful is the available history for Vertex Pharmaceuticals?
- Vertex Pharmaceuticals currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.